Search Results

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2024 LACNETS Conference Speakers Understanding NET Diagnosis: The Work-Up & What You Need to Know About Your NETs Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Understanding NET Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. Understanding Surgery for Liver NETs Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Understanding Carcinoid Crisis Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. Understanding Liver-Directed Therapy Michael Soulen, MD FSIR FCIRSE Interventional Radiologist, University of Pennsylvania Michael C. Soulen, MD FSIR FCIRSE is the Professor of Radiology and Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center and Director of Clinical Research in the Division of Interventional Radiology. His major clinical and research focus for the past 30 years has been image-guided cancer therapy (interventional oncology), with a specific focus on embolotherapy and ablative therapy of solid tumors in the liver and kidney. Animal research includes swine, rabbit, and rat models for liver-directed therapies, investigating novel embolic agents, novel ablation devices, and ultrasound-mediated drug delivery using novel drug-loaded microbubble contrast agents. Clinic trials focus on embolotherapies for primary liver cancers, liver metastases from colorectal and neuroendocrine tumors, and renal cell carcinomas. Current clinical investigations focus on synergy between locoregional and systemic therapies, including 1) pharmacologic modulation of the metabolic stress response under conditions of embolic ischemia; 2) IR therapies as immunostimulants combined with immune checkpoint inhibition, 3) radioembolization with radiosensitizing drugs; 4) serial biopsy for tumor cell culture, rapid drug screening, sequencing and testing in PDX mice, with the goal of personalized precision medicine; and 5) the first international randomized trial comparing embolotherapy techniques for neuroendocrine tumor liver metastases. Dr. Soulen received Research Mentor awards from the University of Pennsylvania Department of Radiology and the North American Neuroendocrine Tumor Society and the Gold Medal from the Society of Interventional Radiology. Understanding PRRT Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). Understanding the Latest in Systemic Treatments & Considerations for Treatment Sequencing Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). NET Tumor Board Panel: Understanding NET Liver Metastases Jaydira Del Rivero, MD Endocrinologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. His master’s degree was in Anatomical Sciences, and his PhD in Biomedical Engineering. He subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty in Radiology at Stanford for 8 years, until moving to OHSU in 2018. Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. This includes adult and pediatric general nuclear medicine imaging with gamma camera and SPECT, PET imaging for oncology, cardiac, and neurologic applications, as well as bone densitometry (DXA imaging). Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is a nationally-recognized expert in this area. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is the current Medical Director of the Healing NET Foundation (HNF). Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. Gangandeep Singh, MD Surgical Oncologist, City of Hope Dr. Singh is an internationally recognized liver and pancreas surgeon. He is the Chief of Surgical Oncology program, Head of the Hepatobiliary & Pancreatic Surgery Program and the Director of the Neuroendocrine Tumor Program at City of Hope Comprehensive Cancer Center (Phoenix). Dr. Singh is a seasoned leader with more than 20 years of experience building and leading several surgical teams to world-wide recognition. Dr. Singh began his faculty academic career at the Keck School of Medicine at University of Southern California (USC) in Los Angeles. From there, he was appointed as the Director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, CA, where he also served as Chair of the Cancer Committee, and Vice President for Fellowship Education. In 2010, City of Hope (Duarte) recruited Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed Professor of Clinical Surgery and as the new Chief of the Division of Surgical Oncology (2011-2019) and hoisted their program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons”, “Best Doctors of America”, “Super Doctors” and “Top Doctors of America.” Prior to his tenure in the Unites States, he earned is his Medical Degree from the Mahatma Gandhi Institute of Medical Sciences, India, and then trained at some of the finest cancer centers across the globe. These institutions include Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University (Paris, France), and the Royal Liverpool University Hospital (Great Britain- England). In the USA, these institutes include the Marion Bessin Liver Center at the Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix), and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He was a panel member of the National Comprehensive Cancer Network (NCCN) for Hepatobiliary Cancers for the last 10 years, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the USA and the rest of the world. Dr. Singh has a very thoughtful, effective, and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multi-disciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology (SSO), Americas Hepato-Pancreato-Biliary Association (AHPBA), Society of Laparoscopic & Robotic Surgeons (SLRS) and other national meetings. An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents. In addition to a large clinical practice, Dr. Singh is passionately advancing cutting-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists, and super-resolution scientists. A leader who is passionate about empowering teams and individuals to achieve their full potential, Dr. Singh has been recognized with several awards and leadership positions. Understanding NET Guidelines Jaydira Del Rivero, MD Endocronologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Understanding the Latest NET Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity. MODERATORS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. MARY DONLEVY LACNETS Board member and NET Patient Advocate Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Beth DeBlase NET Patient Beth was diagnosed in 2016 with metastatic, midgut NET. In that time, she has made aesthetic oncology and integrative therapies her passion. Her mission is to help enhance the quality of life for fellow cancer patients and caregivers, including herself, her four children, and husband. << Go back to the 2024 Annual Conference Page

NETCONNECT Mentors Brent Currie Heather Davis Beth Deblase Michel DeQuevedo Mary Donlevy Denny Organ Shane Peters Aimee Powell Samuel Prentice Valerie Tippy Beth Voyles NETCONNECT is a buddy system to connect NET patients and caregivers with those who can truly relate, listen, provide support and resources. We were all once the newly diagnosed, or the loved one of someone newly diagnosed, and understand what that feels like. Our mentors know how important it is to connect with others who “speak NET,” are familiar with NET terms, medical experts and treatment options. Or just to be reminded to take a deep breath and know you're not alone in this journey. CONNECT WITH A MENTOR Whether you are newly-diagnosed or a long-term survivor, our mentors are here for you. Please send us an email to be connected with a mentor. Email us at info@ncf.net MEET THE NETCONNECT MENTORS Brent Currie BRENT CURRIE NET Patient Brent was diagnosed mid-2017 during an ER visit for blockage and had his large midgut primary NET near the ileum resected. His local oncologist closely monitors bloodwork and scans for new metastases and coordinates results with his multidisciplinary NET center and NET specialist. His past treatments include a second major resection, and lanreotide which he worked hard with his medical team to minimize the severe side-effects unique to him. He is happy to be working with newly diagnosed patients, helping folks understand the terminology and preparing for specialist visits using the NET Vitals worksheet. He is finding this stage of life to be a faith journey just as much as it is a medical journey. He is also a caregiver to his cancer-survivor mom, and enjoys technology and singing/playing music. Watch Brent share about his NET journey here. Heather Davis HEATHER DAVIS LACNETS Associate Director of Advocacy & Outreach Heather was a medical advocate and caregiver for 12 years for her mother, Shaunie, who was diagnosed with pancreatic neuroendocrine cancer in 2012. The efforts required to navigate and manage a rare disease, with complications of Zollinger-Ellison Syndrome, motivated Heather to shift her 20-year marketing career to patient engagement. After learning from and volunteering for LACNETS, she was pleased to join the LACNETS Team in the Fall of 2022. Heather is passionate about supporting those affected by NET. She aspires to bridge the information gap between patients, physicians and healthcare resources. Spending time with her nephews, friends & family brings her levity and joy. Watch Heather and her mother share about their experience with PRRT. Beth Deblase BETH DEBLASE NET Patient Beth was diagnosed in 2016 with metastatic, midgut NET. In that time, she has made aesthetic oncology and integrative therapies her passion. Her mission is to help enhance the quality of life for fellow cancer patients and caregivers, including herself, her four children, and husband. Watch Beth share her inspiring story of strength and resilience titled, “A Shared Experience” here. Michel DeQuevedo MICHEL DEQUEVEDO NET Patient Michel DeQuevedo is a Mexican – Canadian musician living with NETs. After almost 10 years of being “diagnosed” with pretty much every single gastrointestinal condition, changing his diet almost as often as his socks, constantly visiting everybody’s bathrooms and taking tons and tons of non-recreational drugs, he was diagnosed with functional, grade 1, Gastrointestinal NETs, small bowel primary with mets in his liver, appendix, right lung and omentum in September 2021. Michel had an open surgery in December 2021 where some of his factory original parts where removed, along with 90% of the tumors. He is currently on Lanreotide, 120mg every 21 days and can finally have a conversation with someone without having to take bathroom breaks! Michel is an active patient advocate and the founder of NETs México, working to raise awareness about NETs in México and Latin America. He believes keeping a positive attitude is extremely important, as it helps us maintain a clear mind and keeps us moving forward. Watch Michel’s story of diagnosis to patient advocacy here. This video is also available in Spanish, found here . Mary Donlevy MARY DONLEVY NET Patient & LACNETS Board Member Mary was diagnosed in 2005 with a Pancreatic NET. She had a Whipple surgery after her initial diagnosis and a decade of stable disease afterwards on Afinitor and Sandostatin treatments. After a liver resection surgery in 2023 Mary is currently managing her liver metastases with Lanreotide. While living well with this disease for nearly 20 years Mary has raised four children, two of which are identical twins born after her diagnosis. Mary enjoys ocean swimming and traveling with her family. Watch Mary share about her experience in a clinical trial. Watch Mary also share about "scan-xiety," the common anxiety patients sometimes have when undergoing scans here. Watch Mary share her story of living with pancreatic neuroendocrine tumor. Denny Organ DENNY ORGAN NET Patient Denny likes to say that he is living quite well with well-differentiated grade 3 NETs first diagnosed in June of 2020, with significant mets in his liver. Early in his NET journey he dedicated the time to gain as much understanding and knowledge as possible about his disease, treatment options and prognosis. His path has been somewhat unique in having his first-line treatment be Lu-177 PRRT in 2020, and following progression in 2024, two additional rounds of Lu-177. Denny is a very engaged self-advocate and has assembled a strong cross-functional medical team of NET specialists for support. He is a strong believer in integrative oncology being a partner with traditional oncology on his cancer journey and continues to learn and implement strategies for whole body health. Denny’s goal is to keep his cancer, carcinoid heart disease, coronary heart disease and gallstones stable so that he can enjoy the best possible quality of life. He continues to have the time and energy to enjoy a wide variety of hobbies, keep physically active, connect with other NET patients throughout the west coast, and even occasionally provide a patient perspective at NET medical conferences! Watch Denny share his experience with PRRT. Shane Peters SHANE PETERS NET Caregiver & Advocate Shane dove headfirst into the world of neuroendocrine tumors after his mother was diagnosed with stage four, pancreatic NET in 2020. Shane's mom, Ilka, is his best friend and he is determined to do everything and anything possible to make sure his mom forever receives the best cancer care. Shane's mother has undergone a distal pancreatectomy, splenectomy, cholecystectomy, five bland liver embolizations, countless Lanretoide injections and a second liver debulking surgery at the NIH to manage her diagnosis Shane has found such a loving community within LACNETS, in which many of these connections have become dear friends and supporters in his life. Shane is so grateful to be able to give back to the community and help those facing similar journeys as his mother. When Shane is not learning about NETs, he spends his days teaching chorus, piano and music in southern New York! Watch Shane and his mother share their NET journey. Read Shane Peters' blog post 'Scan Results: To Check or Not to Check' Aimee Powell AIMEE POWELL NET Caregiver & Advocate Aimee Powell's involvement with the NET cancer community has its roots in her work as a caregiver for family members diagnosed with pheochromocytoma and paraganglioma (pheo/para). She has worked in an administrative capacity with nonprofits since 2005, and as a professional communicator for over twenty-five years. After her brother's death from malignant paraganglioma, she dedicated herself to raising awareness of para/pheo, and to assisting patients with these rare tumors. Aimee is the founder of the Pheo Para Project, past Executive Director of the Pheo Para Alliance, and currently sits on the board of directors for the SDH-Deficient Cancer Research Advocates. She lives in the Greater Los Angeles area. Watch Aimee share about her pheo/para journey here. Samuel Prentice Jr. SAMUEL PRENTICE JR. NET Patient Samuel is 78, widowed with three children, a retired professional social worker, holistic counselor and educator. He was officially diagnosed in 2017 with NET originating in the small bowel with liver metastases, resulting in the removal of nine feet of small intestine, ileum, iliosacral valve, and his appendix. Samuel then began monthly Sandostatin injections, but in 2018 had a NET colon blockage which led to a colostomy and multiple hospitalizations. In January, 2019 he completed four cycles of PRRT resulting in five years without NET growth. In 2023, he had ⅓ of his neuroendocrine tumorous colon and colostomy removed. The surgeries, however, resulted in struggles with gastrointestinal motility and weight loss. Regardless, Samuel maintains quality of life and energy by swimming and QiGong exercise, singing, dancing, traveling between homes in Southern California and the Indiana Dunes to visit family and friends, continuing his personal holistic growth, progressive political activism and doing one-on-one volunteer counseling with NET patients. He also has fun driving his Acura NSX, and attending hockey, theatre, music, fine art live events and handing out Lollipops! Laugh and sing along as Samuel shares his “Circle Song.” VALERIE TIPPY NET Patient Val was diagnosed with Carcinoid Syndrome in October 2015 with an unknown primary. Along with the unpredictable diarrhea and fatigue, she also deals with sudden shortness of breath, coughing and a hoarse voice. Val’s doctors feel her NET is hiding, so routine tests and scans are done to try and locate the elusive tumor. This can be an ongoing challenge for some NET patients, so getting to the right NET specialist is crucial. In early 2016, Val began doing Lanreotide shots every 4 weeks. When that did not seem to control the symptoms, she was given Lanreotide every 3 weeks, with 5 – 8 rescue shots per day, as needed. In November 2021, her doctor decided to try using an insulin pump with hourly infusions of Octreotide. It was quite a process to find the right dosage, but it has helped tremendously with controlling the syndrome. Val recently retired after spending the last 20 years working with hospitals on designing security systems for patient protection. Her goal is to travel with her husband and spend time with her two adult children. Watch Val share about her NET journey here. Valerie Tippy BETH VOYLES NET Caregiver Beth is the primary advocate and caregiver for her husband Don. Don started on this roller coaster ride when he was diagnosed in November 2019 with midgut NETS with metastases to his liver, pancreas, and bones. He also experiences carcinoid syndrome. He has undergone numerous treatments for his NETS as well as replacement of both his tricuspid and pulmonary heart valves. His symptoms have been very difficult to control. Beth’s professional career as a palliative care nurse provides a unique perspective on the role of advocacy and caregiver. Beth and Don have experienced both highs and lows on this journey, but they continue to take it one day at a time. Traveling when they can and making memories with family and friends along the way. Watch Beth and Don share about their NET journey here. Read Beth's blog post, "What It Means To Be A Caregiver." Beth Voyles

In Loving Memory Giovanna Joyce Imbesi Our founder, hero & inspiration to live life fully… Giovanna Joyce Imbesi, LACNETS founder, was a patient advocate, pianist, and composer based in Los Angeles. She lived fully with neuroendocrine cancer for 14 years and served as a model of compassion, love and kindness. In 2005, after several years of misdiagnosis, Giovanna was diagnosed with metastatic small bowel neuroendocrine cancer. She understood that those with a rare cancer may feel isolated, and sharing similar experiences may lessen the fear of the unknown and offer comfort. It became her mission to help others in the NET community. Her vision was to create a community for a healing exchange of educational resources and emotional support for all affected by neuroendocrine cancer. Against all odds, Giovanna went on to receive an MBA from UCLA Anderson School of Management with the sole intent of launching LACNETS. In 2012, she founded the non-profit GeneratePossibility and the Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) program. Giovanna's physician, Dr. Edward Wolin, was the inaugural speaker for the first LACNETS' patient education meeting. Through LACNETS, Giovanna's aspiration was to create a more "NET-fluent" world. She wanted to change the narrative from associating NET with famous people who die from the disease to raising awareness of the more than 180,000 people who live with the disease. Giovanna wrote, "Each one of us has the ability to help change those numbers in our own community. There are more opportunities to share more about NET and add one more person to the extended global family of NET awareness." Giovanna helped create tools, such as NET VITALS, to improve communication between patients and physicians. She believed that increased awareness equates to more research, which leads to improved treatments and patient outcomes. Giovanna received the 2016 Monica Warner Advocacy Award, as well as the 2019 Cedars-Sinai Patient Leadership Award , for her inspiring work in patient advocacy. Giovanna Joyce Imbesi passed away peacefully on November 24th, 2019. On her last day, Giovanna said with great pride that her greatest legacy was LACNETS. She felt blessed by this community. Giovanna often said, "Aging is a privilege." She celebrated life and connectedness. She believed in practicing gratitude, even appreciating the difficult times. She was grateful for the thousands of neuroendocrine tumor physicians, researchers and healthcare providers who work on the behalf of NET patients every day. The Neuroendocrine Cancer Foundation works daily to honor Giovanna's vision by serving the NET community she established and helping others to live life richly and fully with NET like she did. Participate in the Vision Watch the tribute video honoring Giovanna Joyce Imbesi by Rich Tamayo, Emmy Winning Video Producer & a friend of LACNETS GENERATE POSSIBILITY For Giovanna, music was medicine. Her musical compositions can be heard on "Short Stories - piano music for healing, meditation & relaxation" recorded while in recovery from neuroendocrine cancer surgery. These pieces were inspired by her belief in the healing power of music as a vital element of our well-being. She frequently contributed music to NET causes. A frequent speaker on living with neuroendocrine cancer and the healing power of music, Giovanna was featured as one of six leaders in Integrative Cancer Care at the 2018 Symington Public Forum at Commonweal. We hope that Giovanna's song and her own words, "Give Me Peace," bring some comfort and peace. I’ll always be grateful for Giovanna and her work through LACNETS (now Neuroendocrine Cancer Foundation). The information I learned and connections I made through the educational meetings changed the course of my medical care and helped me to get back to a place where I could enjoy life. — Tom, NET Patient

NET VITALS Download NET VITALS NET VITALS can be filled out digitally or printed and filled out. WHAT IS NET VITALS? LACNETS (now the Neuroendocrine Cancer Foundation) created NET VITALS as a tool for patients and healthcare professionals to share the most important information about a patient’s neuroendocrine tumor, or NET. In just 20 questions, filling out NET VITALS helps you learn the “vitals” of your NET. With all the important information about your disease in one document, NET VITALS gets you and your physician on the same page about your neuroendocrine cancer. Our hope is that NET VITALS will empower patients and improve patient-provider communication. Fill out NET VITALS in preparation for your medical appointment and bring it with you. Carry it with you as an important emergency document. NET VITALS aids with record-keeping and prompts for scan image disks and reports. Watch to learn how to navigate NET VITALS NEWLY DIAGNOSED? Are you newly diagnosed and want to learn the most important information about your neuroendocrine cancer (its “vitals”)? NET VITALS is a guide to biomarkers, terminology, and common procedures and treatments. NET VITALS provides a working document for the patient to understand key vocabulary about their disease and a way to keep track of their status. You are not expected to be familiar with all these terms or know all the answers. NET VITALS may identify questions for you to ask your doctor. LIVING WITH NETS? NET VITALS helps the patient keep current on their disease status and more easily communicate with their physician. NET VITALS can be particularly helpful when seeing a new doctor as part of the multi-disciplinary team or seeking a second opinion. It’s a shortcut to communicate the patient’s disease status in a “snapshot” and all in one place. HOW CAN NET VITALS HELP? Prepare for your appointment with your NET specialist by getting organized and compiling your information and records. Educate yourself on your disease by understanding how this information relates to you. Clarify questions you have for your doctor(s). Makes your medical appointment more efficient. HOW DO I FILL OUT NET VITALS? Download NET VITALS here. Build your NET INTRO or NET elevator speech , which consists of items #2-6 of NET VITALS. Watch the NET VITALS webinar. When you encounter unfamiliar terms and treatments, refer to the resources on the last page of the NET VITALS document. CNETS provides an excellent comprehensive patient guide that can be found here. Filling out NET VITALS can help identify the information that the NET specialist can clarify. As you complete it, you can build your list of questions to bring to your appointment. The Neuroendocrine Cancer Foundation (previously LACNETS) thanks Dr. Dan Li at City of Hope for being our Medical Advisor on NET VITALS. NET VITALS is featured in the following publications: In 2022, NET VITALS was featured in the journal, Pancreas. The study concluded that NET VITALS is a feasible and acceptable self-assessment tool to potentially help patients improve communication about their NET diagnosis/treatment with their physician. Read the full article here. In 2023, NET VITALS was featured in the Journal of Clinical Medicine. The article describes a proposed infrastructure for its implementation into standard clinical care in both academic and community practice settings at City of Hope. We hope that incorporating NET VITALS into standard of care treatment for patients with neuroendocrine tumors may improve patients’ overall clinical care experience. Read the full article here. NOTE: NET VITALS is a document for personal use only. It is not submitted to nor collected by LACNETS. It is a document for you to fill out and take with you to your physician appointment. This document is intended for informational and educational purposes only and is not a substitute for professional medical advice. Always consult with your physician or health care provider.

Terms & Conditions INTRODUCTION These terms and conditions govern your use of this website. These terms and conditions of use are entered into by and between You and the Neuroendocrine Cancer Foundation (“Neuroendocrine Cancer Foundation” “I,” “we,” “us” and “our”). The following terms and conditions of use, together with any documents expressly incorporated by reference (collectively, these “Terms of Use”) govern your access to and use of the Website, its Content, its Social Media and our Apps. By using this website, you agree to be bound by and accept these terms and conditions in full. If you disagree with these terms and conditions or any part of these terms and conditions, you must not use this website. 1. THIS SITE DOES NOT PROVIDE MEDICAL ADVICE General The information contained on the www.neuroendocrinecancer.net website is for general information purposes only. The Neuroendocrine Cancer Foundation assumes no responsibility for errors or omissions in the contents on the Service. In no event shall Neuroendocrine Cancer Foundation be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Neuroendocrine Cancer Foundation reserves the right to make additions, deletions, or modifications to the contents on the Service at any time without prior notice. Informational & Educational Purposes Only The Neuroendocrine Cancer Foundation does not warrant that the website is free of viruses or other harmful components. The Site, Content and/or Services are intended for informational & educational purposes only and are not intended as professional medical advice. By accessing and using the Site and/or Services, such use shall constitute your agreement that the Site and/or Services is not professional medical advice and shall not be relied upon by you as such. Nothing in the content, products or services should be considered or used as a substitute for medical advice, diagnosis or treatment. This site and its services do not constitute the practice of any medical, nursing or other professional healthcare advice, diagnosis or treatment. You should always talk to your healthcare provider for diagnosis and treatment, including your specific medical needs. None of the products or services offered through this website represents or warrants that any particular service or product is safe, appropriate or effective for you. Always consult with your physician or another medical professional first before implementing any of our advice, information, or suggestions. Always consult with a physician or medical professional (not us) before implementing any changes to your diet, medication, lifestyle, exercise regimen, supplement regimen, or health practices. Please only implement any and all changes after consulting with your physician and assessing your own risk. Use of this Site or its Services does not constitute a patient-healthcare provider relationship. Users should always seek the advice of a physician or other qualified healthcare provider with any questions regarding personal health or medical conditions. Patients with healthcare related questions should call or see their physician or other healthcare provider promptly, and should not disregard professional medical advice, or delay seeking it, because of the Content. Never disregard professional medical advice or delay in seeking it because of something you have read on the Site! If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. If you are in the United States and are experiencing a medical emergency, please call 911 or call for emergency medical help on the nearest telephone. Information Is No Substitute for Professional Advice This Site contains only informational and educational material and information. The content on this Site is not a substitute for the advice of your attorney, physician, medical professional, mental health professional, financial advisor, accountant, or any other professional. Testimonials The Testimonials or examples on the Site are simply that: examples. While they are all accurate and authentic, we are not making any claims that you will experience the same or better results from using the Site and/or Services. External links disclaimer The Neuroendocrine Cancer Foundation website may contain links to external websites that are not provided or maintained by or in any way affiliated with the Neuroendocrine Cancer Foundation. Please note that the Neuroendocrine Cancer Foundation does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. The mention of any product, service, organization, activity or therapy on the Website, Social Media or Apps should not be construed as the Neuroendocrine Cancer Foundation endorsement. 2. LICENSE TO USE WEBSITE Unless otherwise stated, the Neuroendocrine Cancer Foundation and/or its licensors own the intellectual property rights in the website and material on the website. Subject to the license below, all these intellectual property rights are reserved. You may view, download for caching purposes only, and print pages or other content from the website for your own personal use, subject to the restrictions set out below and elsewhere in these terms and conditions. You must not: Republish material from this website (including republication on another website); sell, rent or sub-license material from the website; show any material from the website in public; reproduce, duplicate, copy or otherwise exploit material on this website for a commercial purpose; edit or otherwise modify any material on the website; or redistribute material from this website except for content specifically and expressly made available for redistribution. Where content is specifically made available for redistribution, it may only be redistributed within your organization. Acceptable use You must not use this website in any way that causes, or may cause, damage to the website or impairment of the availability or accessibility of the website; or in any way which is unlawful, illegal, fraudulent or harmful, or in connection with any unlawful, illegal, fraudulent or harmful purpose or activity. You must not use this website to copy, store, host, transmit, send, use, publish or distribute any material which consists of (or is linked to) any spyware, computer virus, Trojan horse, worm, keystroke logger, rootkit or other malicious computer software. You must not conduct any systematic or automated data collection activities (including without limitation scraping, data mining, data extraction and data harvesting) on or in relation to this website without the Neuroendocrine Cancer Foundation's express written consent. You must not use this website to transmit or send unsolicited commercial communications. You must not use this website for any purposes related to marketing without the Neuroendocrine Cancer Foundation's express written consent. User content In these terms and conditions, “your user content” means material (including without limitation text, images, audio material, video material and audio-visual material) that you submit to this website, for whatever purpose. You grant to the Neuroendocrine Cancer Foundation a worldwide, irrevocable, non-exclusive, royalty-free license to use, reproduce, adapt, publish, translate and distribute your user content in any existing or future media. You also grant to the Neuroendocrine Cancer Foundation the right to sub-license these rights, and the right to bring an action for infringement of these rights. Your user content must not be illegal or unlawful, must not infringe any third party's legal rights, and must not be capable of giving rise to legal action whether against you or the Neuroendocrine Cancer Foundation or a third party (in each case under any applicable law). You must not submit any user content to the website that is or has ever been the subject of any threatened or actual legal proceedings or other similar complaints. The Neuroendocrine Cancer Foundation reserves the right to edit or remove any material submitted to this website, or stored on the Neuroendocrine Cancer Foundation’s servers, or hosted or published upon this website. Notwithstanding the Neuroendocrine Cancer Foundation’s rights under these terms and conditions in relation to user content, the Neuroendocrine Cancer Foundation does not undertake to monitor the submission of such content to, or the publication of such content on, this website. No warranties This website is provided “as is” without any representations or warranties, express or implied. The Neuroendocrine Cancer Foundation makes no representations or warranties in relation to this website or the information and materials provided on this website. Without prejudice to the generality of the foregoing paragraph, the Neuroendocrine Cancer Foundation does not warrant that: this website will be constantly available, or available at all; or the information on this website is complete, true, accurate or non-misleading. The mention of any product, service, organization, activity or therapy on the Website, Social Media or Apps should not be construed as a Neuroendocrine Cancer Foundation endorsement. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any legal, financial or medical matter you should consult an appropriate professional. Limitations of liability The Neuroendocrine Cancer Foundation assumes no responsibility for any injury or damage to persons or property arising out of or related to the Content, the Website, or the Apps. The Neuroendocrine Cancer Foundation will not be liable to you (whether under the law of contract, the law of torts or otherwise) in relation to the contents of, or use of, or otherwise in connection with, this website: to the extent that the website is provided free-of-charge, for any direct loss; for any indirect, special or consequential loss; or for any business losses, loss of revenue, income, profits or anticipated savings, loss of contracts or business relationships, loss of reputation or goodwill, or loss or corruption of information or data. These limitations of liability apply even if the Neuroendocrine Cancer Foundation has been expressly advised of the potential loss. Exceptions Nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit; and nothing in this website disclaimer will exclude or limit the Neuroendocrine Cancer Foundation’s liability in respect of any: death or personal injury caused by the Neuroendocrine Cancer Foundation’s negligence; fraud or fraudulent misrepresentation on the part of the Neuroendocrine Cancer Foundation; or matter which it would be illegal or unlawful for the Neuroendocrine Cancer Foundation to exclude or limit, or to attempt or purport to exclude or limit, its liability. Social Media Disclaimer By accessing, viewing and/or posting content to any Neuroendocrine Cancer Foundation Social Media Site on the internet, including but not limited to our blogs, Facebook, Twitter, Instagram, YouTube, and online forums, you accept, without limitation or qualification, the following terms of use, as well as any other terms of use required by the company that owns and operates the underlying social media site (e.g.,, any terms of use required by Facebook, Twitter, etc.). If you do not agree to the terms of this Policy, you may not view of post any content to any Neuroendocrine Cancer Foundation Social Media Site on the internet. Your use of Neuroendocrine Cancer Foundation Social Media Sites is acceptance of this Policy and has the same effect as if you had actually physically signed an agreement. Rules of Conduct DO NOT transmit materials in any manner that is unlawful, disruptive, threatening, profane, abusive, harassing, embarrassing, tortuous, defamatory, obscene, libelous, or is an invasion of another’s privacy, is hateful or racially, ethnically or otherwise objectionable as solely determined by the Neuroendocrine Cancer Foundation staff. DO NOT impersonate any person or entity or falsely state or otherwise misrepresent your affiliation with a person or entity. DO NOT transmit any unsolicited or unauthorized advertising, promotional materials, or any other form of solicitation. DO NOT transmit any materials that contain any kind of virus, spyware, or malware. DO NOT violate another’s copyright or intellectual property. DO NOT post any proprietary, confidential, sensitive, or nonpublic information. LACNETS RESERVES THE RIGHT TO (but is not obligated) to do any of the following: Moderate all content; Remove information, language, or any communication considered offensive and/or fails to conform with these terms of use; Edit or delete any communications posted on the Site or Social Media, regardless of whether such communications violate these standards; Block users who violate these guidelines. Exceptions Nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit; and nothing in this website disclaimer will exclude or limit the Neuroendocrine Cancer Foundation’s liability in respect of any: death or personal injury caused by the Neuroendocrine Cancer Foundation’s negligence; fraud or fraudulent misrepresentation on the part of the Neuroendocrine Cancer Foundation; or matter which it would be illegal or unlawful for the Neuroendocrine Cancer Foundation to exclude or limit, or to attempt or purport to exclude or limit, its liability. Reasonableness By using this website, you agree that the exclusions and limitations of liability set out in this website disclaimer are reasonable. If you do not think they are reasonable, you must not use this website. Other parties You accept that, as a limited liability entity, the Neuroendocrine Cancer Foundation has an interest in limiting the personal liability of its officers and employees. You agree that you will not bring any personal claim against the Neuroendocrine Cancer Foundation's officers or employees with respect to any losses you suffer in connection with the website. You agree that the limitations of warranties and liability set out in this website disclaimer will protect the Neuroendocrine Cancer Foundation’s officers, employees, agents, subsidiaries, successors, assigns and sub-contractors as well as the Neuroendocrine Cancer Foundation. Unenforceable provisions If any provision of this website disclaimer is, or is found to be, unenforceable under applicable law, that will not affect the enforceability of the other provisions of this website disclaimer. Indemnity You hereby indemnify the Neuroendocrine Cancer Foundation and undertake to keep the Neuroendocrine Cancer Foundation indemnified against any losses, damages, costs, liabilities and expenses (including without limitation legal expenses and any amounts paid by the Neuroendocrine Cancer Foundation to a third party in settlement of a claim or dispute on the advice of the Neuroendocrine Cancer Foundation’s legal advisers) incurred or suffered by the Neuroendocrine Cancer Foundation arising out of any breach by you of any provision of these terms and conditions, or arising out of any claim that you have breached any provision of these terms and conditions. Breaches of these terms and conditions Without prejudice to the Neuroendocrine Cancer Foundation’s other rights under these terms and conditions, if you breach these terms and conditions in any way, the Neuroendocrine Cancer Foundation may take such action as the Neuroendocrine Cancer Foundation deems appropriate to deal with the breach, including suspending your access to the website, prohibiting you from accessing the website, blocking computers using your IP address from accessing the website, contacting your internet service provider to request that they block your access to the website and/or bringing court proceedings against you. Variation The Neuroendocrine Cancer Foundation may revise these terms and conditions from time-to-time. Revised terms and conditions will apply to the use of this website from the date of the publication of the revised terms and conditions on this website. Please check this page regularly to ensure you are familiar with the current version. Assignment The Neuroendocrine Cancer Foundation may transfer, sub-contract or otherwise deal with the Neuroendocrine Cancer Foundation’s rights and/or obligations under these terms and conditions without notifying you or obtaining your consent. You may not transfer, sub-contract or otherwise deal with your rights and/or obligations under these terms and conditions. Severability If a provision of these terms and conditions is determined by any court or other competent authority to be unlawful and/or unenforceable, the other provisions will continue in effect. If any unlawful and/or unenforceable provision would be lawful or enforceable if part of it were deleted, that part will be deemed to be deleted, and the rest of the provision will continue in effect. Entire agreement These terms and conditions constitute the entire agreement between you and the Neuroendocrine Cancer Foundation in relation to your use of this website, and supersede all previous agreements in respect of your use of this website. The Neuroendocrine Cancer Foundation is also known as the Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS). You may contact the Neuroendocrine Cancer Foundation by email at info@neuroendocrinecancer.net . Disclaimer The information contained on the www.neuroendocrinecancer.net website is for general information purposes only. The Neuroendocrine Cancer Foundation assumes no responsibility for errors or omissions in the contents on the Service. In no event shall the Neuroendocrine Cancer Foundation) be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Neuroendocrine Cancer Foundation reserves the right to make additions, deletions, or modification to the contents on the Service at any time without prior notice. The Neuroendocrine Cancer Foundation does not warrant that the website is free of viruses or other harmful components. External links disclaimer The Neuroendocrine Cancer Foundation website may contain links to external websites that are not provided or maintained by or in any way affiliated with the Neuroendocrine Cancer Foundation. Please note that the Neuroendocrine Cancer Foundation does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. Last updated February 17, 2025

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. A new episode will be released every month. Be sure to subscribe to our podcast to receive notifications when new episodes are released! EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. LISTEN NOW EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. LISTEN NOW EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques & Sequencing) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. LISTEN NOW EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part I: Overview and Ablative Techniques Including Histotripsy) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. LISTEN NOW EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. LISTEN NOW EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. LISTEN NOW EPISODE 35: NEN TREATMENTS: FOCUS ON CHEMOTHERAPY What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. LISTEN NOW EPISODE 34: NET TREATMENTS: FOCUS ON PRRT What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. LISTEN NOW EPISODE 33: FOCUS ON TARGETED THERAPIES What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. LISTEN NOW EPISODE 32: FOCUS ON SOMATOSTATIN ANALOGUES (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. LISTEN NOW EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. LISTEN NOW EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. LISTEN NOW EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. LISTEN NOW EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community. LISTEN NOW EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. LISTEN NOW EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. LISTEN NOW EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. LISTEN NOW EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of hindgut NETs and appendix NET. LISTEN NOW EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. LISTEN NOW EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETs How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutch Cancer Center in Seattle answers 10 common questions about small bowel NETs. LISTEN NOW EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYMDROME (ZES) Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. LISTEN NOW EPISODE 19: BEYOND THE BASICS: THE PATHOLOGY OF NET Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. LISTEN NOW EPISODE 18: MENTAL HEALTH & NETS What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. LISTEN NOW EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. LISTEN NOW EPISODE 15: PSYCHO-ONCOLOGY What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. LISTEN NOW EPISODE 14: PALLIATIVE CARE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. LISTEN NOW EPISODE 13: NET ONCOLOGY Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. LISTEN NOW EPISODE 12: PHEO & PARA In honor of Pheo Para Awareness Week, NET endocrinologist and medical oncologist Dr. Jaydira Del Rivero of the National Cancer Institute answers ten common questions about pheochromocytoma and paraganglioma (PPGL). Dr. Del Rivero defines PPGL and describes the unique symptoms, genetic testing, and treatment options for PPGL. LISTEN NOW EPISODE 11: PATHOLOGY FOR NETS How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. LISTEN NOW EPISODE 10: PRRT (PART III) How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT LISTEN NOW EPISODE 9: PRRT (PART II) Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. LISTEN NOW EPISODE 8: PRRT (PART I) Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. LISTEN NOW EPISODE 7: IMAGING OF NETS Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. LISTEN NOW EPISODE 6: DECISION-MAKING FOR NETS How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy. LISTEN NOW EPISODE 5: TREATMENT FOR NETS What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers 10 common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. LISTEN NOW SPECIAL EPISODE: THE LACNETS STORY In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi , the LACNETS Founder, whose vision and dedication inspires us all. LISTEN NOW EPISODE 4: NET BASICS Newly diagnosed? Or need to brush up on your NET basics? In our fourth podcast episode, medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. LISTEN NOW EPISODE 3: SURGERY FOR NETS To cut or not to cut? A common crossroad neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope joins the podcast to answer the top 10 surgery questions for NETs. LISTEN NOW EPISODE 2: DIARRHEA & NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. LISTEN NOW EPISODE 1: NUTRITION FOR NETS For our first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, and recommended diet. LISTEN NOW THANKS TO OUR SPONSORS